Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network.

Carlo LavalleMarco Valerio MarianiAgostino PiroMichele MagnocavalloGiampaolo VettaSara TrivignoGiovanni Battista Forleo Domenico Giovanni Della RoccaMassimo UguccioniVincenzo Russo Francesco SummariaLuca Di Lullo

Published in: Journal of clinical medicine (2022)

DOACs presented an acceptable safety profile in the current post-market analysis. However, rivaroxaban and apixaban were associated with more favorable safety profiles as compared to dabigatran, while rivaroxaban provoked statistically significantly fewer ICH events as compared to apixaban.

Keyphrases

direct oral anticoagulants
atrial fibrillation
adverse drug
venous thromboembolism
electronic health record
emergency department
quality improvement
health insurance